Figure 3.

Gpr17 regulates oligodendrocyte survival by controlling Xaf1 expression. A, Relative numbers of viable oligodendrocytes after treatment with vehicle or 12.5 mm LPC for 24 h. The oligodendrocytes were treated with 10 mm pranlukast or 10 nm MDL29951 for 24 h before LPC treatment. Data are means ± SEM from three independent experiments. *p < 0.05, **p < 0.01, two-way ANOVA. B, Relative numbers of viable OPCs treated with indicated shRNAs and 10 mm pranlukast for 48 h. The effect on Gpr17 levels was confirmed by Western blot analysis. Data are means ± SEM from three independent experiments. *p < 0.05, two-way ANOVA. C, Relative numbers of viable OPCs overexpressing Gpr17 or transfected with control vector (Gfp) for 48 h. Overexpression of Gpr17 was confirmed by Western blot analysis. Data are means ± SEM from three independent experiments. *p < 0.05, Student's t test. D, Primary rat OPCs were transfected with control Gfp and Gpr17-expressing vectors and cultured in the differentiation medium for 48 h. Cleaved caspase 3 was assessed by Western blot analysis. E, Relative numbers of viable OPCs treated with indicated shRNAs (shScr indicates scrambled control) and 10 nm MDL29951 for 48 h. Data are means ± SEM from three independent experiments. *p < 0.05, two-way ANOVA. F, Western blot analysis of cleaved caspase 3 in oligodendrocytes treated with 10 nm MDL29951 in the differentiation medium for 48 h. Veh, Vehicle; Pran, pranlukast; MDL, MDL29951; shScr, scrambled control.